Tom Boone

TL;DR: Data show that OPG can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity.

TL;DR: In this paper, the authors showed that specific Ang2 inhibition may represent an effective anti-angiogenic strategy for treating patients with solid tumors, and they showed that anti-Ang2 therapy also prevented VEGF-stimulated neovascularization in a rat corneal model of angiogenesis.

TL;DR: The tumor neurosis factor homolog APRIL stimulates in vitro proliferation of primary B and T cells and increases spleen weight due to accumulation of B cells in vivo, indicating that APRIL and/or TALL-1 signaling via BCMA and TACI are required for generation of humoral immunity.

TL;DR: These studies identify a previously unknown T-cell co-stimulatory pathway as a potential therapeutic target and isolate a mouse homolog of human LIGHT, a member of the tumor necrosis factor (TNF) ‘superfamily’.

TL;DR: The identification and characterization of the receptor for TALL-1 provides useful information for the development of a treatment for B cell-mediated autoimmune diseases such as systemic lupus erythematosus.